Literature DB >> 21525854

Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo.

Ignacio López1, M Encarnación Rodríguez-Ortiz, Yolanda Almadén, Fátima Guerrero, A Montes de Oca, Carmen Pineda, Vicky Shalhoub, Mariano Rodríguez, Escolástico Aguilera-Tejero.   

Abstract

Fibroblastic growth factor 23 (FGF23) is a bone-derived hormone that has a pivotal role in the pathogenesis of mineral disorders in chronic kidney disease. To study the effect of parathyroid hormone (PTH) on FGF23, rats were parathyroidectomized for a week and then implanted with constant-delivery infusion pumps to provide vehicle, a physiological, or a threefold supraphysiological dose of parathyroid hormone. Parathyroidectomy resulted in a significant decrease in blood ionized calcium, FGF23, and calcitriol along with an increase in phosphorus concentrations. PTH replacement produced a dose-dependent increase in ionized calcium and FGF23 with decreased phosphorus. Calcitriol was also increased but there was no dose effect of PTH treatment. To maintain normal plasma calcitriol levels, two additional groups of parathyroidectomized rats were given calcitriol and temporarily treated with vehicle or the supraphysiological dose of PTH. FGF23 was significantly increased by calcitriol in the vehicle-treated rats but was not further increased above that in rats given the supraphysiological dose of PTH in the absence of calcitriol. Klotho expression in the kidney decreased after parathyroidectomy but was restored by hormone supplementation. Hence, our results show a direct and an indirect effect of PTH on FGF23 secretion, the latter through changes in calcitriol concentrations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525854     DOI: 10.1038/ki.2011.107

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  64 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  FGF23 and PTH--double agents at the heart of CKD.

Authors:  Justin Silver; Mariano Rodriguez; Eduardo Slatopolsky
Journal:  Nephrol Dial Transplant       Date:  2012-03-23       Impact factor: 5.992

3.  Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.

Authors:  Stuart M Sprague; James B Wetmore; Konstantin Gurevich; Gerald Da Roza; John Buerkert; Maureen Reiner; William Goodman; Kerry Cooper
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-14       Impact factor: 8.237

Review 4.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

5.  Histomorphometric diagnostics of renal osteopathy in chronic dialysis patients at high risk of cardiovascular disease.

Authors:  K Žamboch; K Krejčí; J Škarda; M Tichý; I Überall; P Skýpalová; K Langová; D Stejskal; M Švesták; J Zahálková; V Ščudla; J Zadražil
Journal:  Int Urol Nephrol       Date:  2015-05-01       Impact factor: 2.370

6.  Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.

Authors:  Mark R Hanudel; Kristine Chua; Maxime Rappaport; Victoria Gabayan; Erika Valore; David Goltzman; Tomas Ganz; Elizabeta Nemeth; Isidro B Salusky
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-12

Review 7.  Non-renal-Related Mechanisms of FGF23 Pathophysiology.

Authors:  Mark R Hanudel; Marciana Laster; Isidro B Salusky
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 8.  Inflammation regulates fibroblast growth factor 23 production.

Authors:  Connor Francis; Valentin David
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

9.  The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program.

Authors:  Georges Saab; Andrew S Bomback; Samy I McFarlane; Suying Li; Shu-Cheng Chen; Peter A McCullough; Adam Whaley-Connell
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

Review 10.  The use of fibroblast growth factor 23 testing in patients with kidney disease.

Authors:  Edward R Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.